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Summary
 
Little is known about the events triggering lymphocyte invasion of the pancreatic islets in pre-
lude to autoimmune diabetes. For example, where islet-reactive T cells first encounter antigen
has not been identified. We addressed this issue using BDC2.5 T cell receptor transgenic mice,
which express a receptor recognizing a natural islet beta cell antigen. In BDC2.5 animals, acti-
vated T cells were found only in the islets and the lymph nodes draining them, and there was a
close temporal correlation between lymph node T cell activation and islet infiltration. When
naive BDC2.5 T cells were transferred into nontransgenic recipients, proliferating cells were
observed only in pancreatic lymph nodes, and this occurred significantly before insulitis was
detectable. Surprisingly, proliferation was not seen in 10-day-old recipients. This age-depen-
dent dichotomy was reproduced in a second transfer system based on an unrelated antigen arti-
ficially expressed on beta cells. We conclude that beta cell antigens are transported specifically
to pancreatic lymph nodes, where they trigger reactive T cells to invade the islets. Systemic or
extrapancreatic T cell priming, indicative of activation via molecular mimicry or superantigens,
was not seen. Compromised presentation of beta cell antigens in the pancreatic lymph nodes of
juvenile animals may be the root of a first “checkpoint” in diabetes progression.
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I
 
nsulin-dependent diabetes mellitus (IDDM)
 
1
 
 is caused by
autoimmune destruction of the insulin-producing beta
cells of the pancreatic islets of Langerhans (for reviews, see
references 1 and 2). Much of our current knowledge about
the complex pathogenesis of IDDM derives from studies
on the nonobese diabetic (NOD) mouse, which succumbs
to a disease closely resembling that of human patients (for a
review, see reference 3). These studies have revealed an in-
flux of inflammatory cells into the islets, termed insulitis,
starting at 
 
z
 
4–5 wk after birth; however, significant beta
cell destruction, and consequently diabetes, is not evident
until 
 
z
 
12 wk of age. Of the cells that constitute the insu-
litic lesion, T cells appear to play a primary role. Nonethe-
less, other cell types—such as B cells, macrophages, and
dendritic cells (DCs)—also contribute to disease progres-
sion.
The events responsible for triggering IDDM in a suscep-
tible individual are clouded in uncertainty. The role of en-
vironmental factors (4–6), the nature of the initiating in-
flammatory cell (7, 8), and the identity of the inciting
antigen(s) (9–11) have all been vigorously debated. Among
the important unresolved issues is where the initial stimula-
tion of naive, islet-reactive T cells takes place. One possi-
bility is that it occurs within the islets, where autoantigens
are presented either by the beta cells that synthesize them
or by APCs in the vicinity. This scenario might seem un-
likely given the body of data establishing that naive T cells
circulate through peripheral lymphoid organs rather than
through tissues (12), but it could be that either the pancre-
atic islets or islet-reactive T cells are special in this respect.
Another possible site of initial stimulation is in the LNs
draining the pancreas. This is an attractive option because
of its analogy to what happens when foreign proteins are
 
1
 
Abbreviations used in this paper:
 
 CFSE, 5,6-carboxyfluorescein diacetate suc-
cinimidyl ester; DC, dendritic cell; IDDM, insulin-dependent diabetes mel-
litus; IIL, intraislet lymphocyte; ILN, inguinal lymph node; MLN, mesen-
teric lymph node; NOD, nonobese diabetic; OT-I, OVA-specific CD8
 
1
 
 T
cells; PLN, pancreatic lymph node; RAG, recombination activating gene;
RIP, rat insulin promoter; RLN, renal lymph node; tg, transgenic. 
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introduced through the skin: antigen is captured by imma-
ture Langerhans cells, ferried to the draining LNs, and is
presented there to recirculating naive T cells by the now-
mature Langerhans cells (13). However, to date there is lit-
tle experimental evidence of such a sequence of events in
the progression of diabetes or, indeed, of any autoimmune
disease. A third possibility is that potentially diabetogenic T
cells are first stimulated systemically or at a distant site, ei-
ther in a tissue or in one of the peripheral lymphoid organs.
This proposed scenario reflects arguments that islet-reactive
T cells are “awakened” upon activation by cross-reactive
environmental antigens or microbial superantigens (5, 6).
To distinguish between these different possibilities, we
took advantage of the BDC2.5 TCR transgenic (tg) model
of diabetes (14). BDC2.5 tg mice carry the rearranged
TCR 
 
a
 
 (V
 
a
 
1) and 
 
b
 
 (V
 
b
 
4) chain genes from a diabetoge-
nic, beta cell–specific, CD4
 
1
 
 T cell clone isolated from a
diabetic NOD mouse (15, 16). T cells expressing the trans-
gene-encoded receptor are efficiently selected on the
NOD background and contribute substantially to the pe-
ripheral T cell repertoire. Nevertheless, the autoreactive T
cells appear to ignore the beta cells for the first 2 wk of
life. At that time, they abruptly invade the islets and insuli-
tis progresses rapidly, such that at 3–4 wk of age almost all
islets are heavily infiltrated. Thus, the initiation of autoim-
mune attack is especially clear and synchronous in BDC2.5
mice, suggesting that this model might prove highly advan-
tageous for studying the triggering of IDDM.
Here we present results from two types of experiments—
monitoring T cell activity at different sites in prediabetic
BDC2.5/NOD tg mice, and tracking the behavior of naive
BDC2.5 T cells adoptively transferred into nontransgenic,
NOD-background hosts. The data prompt us to conclude
that diabetogenic T cells are first stimulated in the LNs im-
mediately draining the pancreas, and that antigen availability
at this site is a critical determinant of disease initiation.
 
Materials and Methods
 
Mice.
 
The generation of BDC2.5/NOD TCR tg mice has
been described previously (14, 17). C
 
a
 
0
 
/NOD and recombination
activating gene (RAG)
 
0
 
/NOD animals were obtained by repeti-
tively backcrossing null mutations in either the TCR-
 
a
 
 (18) or
RAG-1 (19) genes onto the NOD/Lt genetic background fol-
lowed by intercross to obtain homozygous mutant mice (mice used
in the present experiment were at the sixth and eighth backcross
generation, respectively). BDC2.5 animals were typed by flow cy-
tometry using mAbs against CD4 and V
 
b
 
4. The C
 
a
 
 and RAG
null mutations were identified by Southern blotting or flow cyto-
metric analysis of PBLs. These animals were maintained in the In-
stitut de Génétique et de Biologie Moléculaire et Cellulaire animal
facility in Strasbourg, under Ministère de l’Agriculture (Agrément
67227) and European Economic Community guidelines. Genera-
tion of rat insulin promoter (RIP)-mOVA mice and mice express-
ing a transgenic CD8-restricted OVA-specific TCR (OT-I) has
also been described (20), and these lines were maintained in the
Walter and Eliza Hall Institute animal facility in Melbourne.
 
Isolation of Intraislet Lymphocytes.
 
The pancreatic LNs (PLNs)
were removed, and the remaining pancreas tissue was carefully
cut into small pieces using fine scissors. 5–10 islet infiltrates (easily
identified in BDC2.5 pancreata as “bubbles” surrounding normal
islet tissue) were hand-picked under a dissecting microscope, and
converted into a single-cell suspension for flow cytometry analysis.
 
Insulitis.
 
Thin sections from Bouin’s solution–fixed, paraffin-
embedded pancreas specimens were stained with hematoxylin-
eosin and scored for insulitis—a minimum of 40 independent is-
lets per animal on multiple sections.
 
Antibodies and Flow Cytometry.
 
T cell analysis was performed as
described previously (21). The following mAbs were used: PE-con-
jugated CD4 (Caltag); biotin- or allophycoerythrin-conjugated
CD8 (Caltag); FITC-conjugated CD69 (PharMingen); IM7, spe-
cific for CD44 (22); Mel14, specific for CD62L (23); and B20.1,
specific for V
 
a
 
2 (24). Biotinylated Ab was revealed by aminometh-
ylcoumarin-conjugated streptavidin and the other Abs by Texas
red–conjugated goat anti–rat IgG (Jackson ImmunoResearch Labs).
 
CFSE Labeling and Adoptive Transfer.
 
For the BDC2.5 sys-
tem, single-cell suspensions from pooled spleens were depleted of
erythrocytes in 0.83% NH
 
4
 
Cl, adjusted to 10
 
7
 
/ml in PBS, and in-
cubated for 10 min at 37
 
8
 
C in the presence of 2.5 
 
m
 
M 5,6-car-
boxyfluorescein diacetate succinimidyl ester (CFSE; Molecular
Probes) prepared as a 5 mM stock solution in DMSO. After incu-
bation, the cells were washed twice with RPMI supplemented
with 5% FCS, and adjusted to 10
 
8
 
/ml. In each experiment, 200 
 
m
 
l
(2 
 
3 
 
10
 
7
 
 cells) were injected, intravenously for adult and intra-
peritoneally for 10-d-old recipients. These two routes of inocula-
tion were comparable, since homing to the PLNs followed iden-
tical kinetics (data not shown). At various times after inoculation,
LNs were removed and analyzed for the presence of CFSE-
labeled cells.
For the OT-I system (20, 25), single-cell suspensions from
OT-I/RAG
 
0
 
 mice were depleted of CD24
 
1
 
 and CD4
 
1
 
 cells by
treatment with J11d and RL-172 mAbs (26, 27) and comple-
ment. The proportion of OT-I cells was then determined by
flow cytometry, staining for CD8 and V
 
a
 
2. 2 
 
3 
 
10
 
6
 
 OT-I cells
were injected intravenously into adult or 10-d-old RIP-mOVA
mice. After 67 h, the LNs were removed and assessed for CFSE-
labeled cells as described (20, 25).
 
Results
 
Activated BDC2.5 Tg T Cells Reside Specifically in the Pan-
creatic Islets and Their Draining LNs.
 
As a first step, we ex-
amined the activation status of T cells located at different
sites in the periphery of BDC2.5 TCR tg mice (Fig. 1).
Very few CD4
 
1
 
V
 
b
 
4
 
1
 
 cells in the spleen and most LNs, in-
cluding the inguinal (ILN) and mesenteric (MLN), ex-
pressed the activation marker CD69; in contrast, a large
proportion of cells in the PLNs and within the pancreatic
islets (intraislet lymphocytes, IILs) had an activated pheno-
type (Fig. 1 A). This activation was linked to the presence
of the transgene, as these large populations of CD69
 
1
 
 cells
were not found in PLNs of nontransgenic littermates (data
not shown). The activated PLN and IIL cells were similar
to each other and typical of other activated T cells in their
augmented expression of CD44 and diminished display of
CD62L (Fig. 1 B). These findings suggest that the antigen
that triggers BDC2.5 tg T cells is present specifically in the
pancreas and the immediately draining LNs. This notion was
supported by an analysis of TCR 
 
a
 
 chain usage by T cells
at the different sites: in the PLNs, cells expressing the en- 
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dogenously encoded V
 
a
 
2 chain were underrepresented
(and presumably those displaying the transgene-encoded
chain overrepresented), whereas the opposite was true in
other nodes, such as the ILNs (Fig. 1 C).
 
There Is a Close Temporal Correlation between the Appearance
of Activated BDC2.5 T cells in the PLNs and of Infiltrated Is-
lets.
 
The presence of activated T cells in both the islets
and draining LNs of BDC2.5 tg mice raised the question of
whether they were first stimulated at the former site or at
the latter. Priming may be quite synchronous in individual
BDC2.5 animals as insulitis begins abruptly between days
15 and 18 after birth. Therefore, we performed a careful
kinetic analysis, day by day beginning on day 12, scoring
the percentage of CD69
 
1
 
 T cells in the PLNs versus the
proportion of islets containing invading lymphocytes. As il-
lustrated in Fig. 2, there was generally a good correlation
between the fraction of activated PLN cells and infiltrated
islets. On day 14, a few mice had CD69
 
1
 
 cells in the PLNs
in the absence of detectable insulitis, but this was not a
general observation. On the basis of these data, we con-
cluded that activation of T cells in the PLNs and islet infil-
tration had a close temporal correlation, but could not es-
tablish conclusively which of the two was the primary
event.
 
Proliferating Cells Are Localized Specifically in the PLNs
Shortly after Transfer of Naive BDC2.5 T Cells.
 
A possible
reason for the inconclusive results in the preceding experi-
ment is that, although it is considerably more synchronous
than in standard NOD mice, the initiating event in
BDC2.5 transgenics is still scattered over a window of 3 or
4 d in different individuals, rendering it difficult to pre-
cisely “capture” in a significant number of animals. There-
fore, we switched to an adoptive transfer system, hoping
that if the BDC2.5 T cells entered the circulation at exactly
the same time in different animals, disease initiation would
be highly synchronous. The transfer system is depicted in
Fig. 3 A: splenocytes are removed from BDC2.5 tg mice,
labeled in vitro with the cytoplasmic dye CFSE, and trans-
ferred into NOD-background recipients; some days later,
different lymphoid organs are removed, and homing and
proliferation are assayed by cytofluorimetric assessment of
the presence and degree of dilution of CFSE staining.
When CFSE-labeled cells proliferate, their fluorescence is
distributed equally between the two daughter cells, result-
ing in a 2
 
n
 
-fold dilution in fluorescence intensity, where
 
 n
 
represents the number of cell divisions.
Fig. 3 B presents histograms of CFSE staining in
CD4
 
1
 
V
 
b
 
4
 
1
 
 cells from spleen and a variety of LNs 3 d after
Figure 1. Activated lymphocytes in
BDC2.5 mice. (A) CD69 expression on
CD41Vb41 T cells from spleen (SP), ILNs,
MLNs, PLNs, and IILs from a young
BDC2.5 mouse. The percentage of positive
cells included within the indicated region is
shown for each histogram. (B) Representa-
tive biparametric CD69/CD44 and CD69/
CD62L histograms of gated CD41 T cells
from the same sources. (C) Underrepresen-
tation of nontransgenic Va21 TCRs among
CD691CD41 lymphocytes in PLNs com-
pared with ILNs from BDC2.5 mice.
Dashed line, an approximation of the per-
centage of Va21 cells within CD41 T cells
in the whole lymphoid system of the ana-
lyzed mouse (estimated from pooled data of
spleen and LN T cells).
Figure 2. Temporal correla-
tion between the activation of T
cells in PLNs and islet infiltration
in young BDC2.5 mice. Per-
centage of infiltrated islets was
plotted against the percentage of
CD691 among CD41 T cells in
PLNs in BDC2.5 mice of differ-
ent ages. Each dot represents an
individual mouse. 
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transfer of splenocytes from a young, adult BDC2.5 mouse
into a young, adult C
 
a
 
0
 
/NOD host. CFSE-labeled cells
were present in the spleen and the many LNs examined,
but only in the PLNs was there significant dilution of label,
signaling activation followed by proliferation. These data
from the transfer system closely mimic those derived from
regular BDC2.5 animals: the antigen that triggers BDC2.5
T cells is present in the LNs immediately draining the pan-
creas, but not in the other peripheral lymphoid organs ex-
amined.
It has been hypothesized that insulitis in NOD mice, in
particular infiltration of CD4
 
1
 
 T cells, requires initial islet
cell damage mediated by CD8
 
1
 
 T cells (7, 8, 28–34). In
our experiments, proliferating BDC2.5 T cells were found
in the PLNs of C
 
a
 
0
 
/NOD mice, which suggests that trans-
port of the relevant autoantigen to this node does not re-
quire prior islet cell destruction by T cells displaying other
 
a
 
/
 
b
 
 specificities. In fact, PLN-specific proliferation of
BDC2.5 cells was observed after transfer into standard
NOD, C
 
a
 
0
 
/NOD, and RAG
 
0
 
/NOD hosts—to a similar
extent (Fig. 3 C) and with similar kinetics (data not
shown). Thus, other lymphocytes neither inhibit nor are
required for BDC2.5 cells to access their antigen in the
PLNs.
 
Proliferating BDC2.5 T Cells Appear in the PLNs before Is-
let Infiltration Can Be Detected.
 
We then exploited the
transfer system to address the question of whether naive
BDC2.5 T cells are first stimulated in the islets or in their
draining LNs. C
 
a
 
0
 
/NOD mice were used as recipients to
preclude interference from host 
 
a
 
/
 
b
 
 T cells and to simplify
the detection of transferred cells, particularly in the islets.
CFSE-labeled splenocytes from young, adult BDC2.5
transgenics were injected into nontransgenic C
 
a
 
0
 
/NOD
recipients of similar age and, at various times after injection,
the relevant LNs were removed for cytofluorimetric analy-
sis, and pancreas sections were prepared for histological
evaluation.
Results from a typical experiment are summarized in
Fig. 4. Already on day 1 after transfer, CFSE-labeled donor
cells appeared in both the PLNs and ILNs, but without
proliferation for the first 2 d. On day 3, PLN cells abruptly
exhibited strong dilution of the CFSE label, signifying pro-
liferation, and staining levels gradually diminished over the
next 5 d. ILN cells showed no dilution of the CFSE label
on day 3, but a few cells with fully reduced staining could
be detected 1 d later, their low and uniform level of CFSE
indicative of recirculating cells. Substantial numbers of such
cells were found on day 5, and even more on day 8. Islet
infiltration paralleled the appearance of recirculating cells in
the ILNs, though with some delay—not detectable on day
3, rare for the next 2 d, substantial only on day 8.
Clearly, then, proliferating cells emerged in the PLNs
before the onset of islet invasion. A similar dissociation be-
tween the two events was seen in seven independent ex-
periments.
 
The BDC2.5 Antigen Cannot Be Detected in the PLNs of
Very Young NOD Mice.
 
Previous studies have highlighted
two “checkpoints” in the progression of disease in BDC2.5
TCR tg mice (14, 17, 35), and these seem to be character-
istic of standard NOD mice as well (36). Checkpoint 1
concerns the onset of insulitis: even though BDC2.5 trans-
genics harbor plenty of T cells expressing an islet beta cell–
reactive receptor from shortly after birth, invasion of the is-
lets is not detectable until 15–18 d of age. In theory, this
delay could reflect either T cell incompetence or antigen
unavailability in the very young mice.
Figure 3. Proliferation of CFSE-labeled transferred BDC2.5 spleen
cells occurs selectively in PLNs. (A) The transfer protocol: splenocytes
from BDC2.5 mice are labeled with CFSE in vitro, then transferred to
Ca0/NOD recipients. Proliferation of the transferred CD41Vb41 T cells
is visualized, a few days after transfer, as progressive decrease of labeling
intensity in individual cells. (B) CFSE label 3 d after transfer to Ca0/
NOD recipients in PLNs, ILNs, axillary LNs (ALN), cervical LNs
(CLN), MLNs, RLNs, iliac LNs (ILILN), parathymic LNs (PATLN), and
spleen. (C) Proliferation in PLNs occurs in Ca0/NOD, RAG0/NOD,
and in normal NOD recipients. 
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To evaluate the first explanation, we compared the abil-
ity of splenic T cells removed from 10-d-old and adult
BDC2.5 transgenics to proliferate in the PLNs after transfer
into adult C
 
a
 
0
 
/NOD hosts (Fig. 5 A). The T cells from
10-d-old mice appeared to be just as active as those from
adults, proliferating cells being detectable in the PLNs with
similar kinetics and to a similar degree. Thus, T cell incom-
petence is unlikely to be the explanation for the delayed
onset of insulitis.
To assess the second explanation, antigen unavailability,
we performed the reciprocal experiment, comparing the
ability of splenic T cells from adult BDC2.5 transgenics to
proliferate in the PLNs of 10-d-old and adult C
 
a
 
0
 
/NOD
recipients (Fig. 5 B). Here, there was a striking difference
in behavior: as usual, proliferating T cells appeared in the
PLNs 3 d after transfer into adult hosts, but did not when
 
introduced into 10-d-old mice. These results argue that the
delayed onset of insulitis in BDC2.5 tg mice reflects un-
availability of the autoantigen in juvenile animals.
 
Another Beta Cell–derived Autoantigen Is Undetectable in the
PLNs of Very Young Mice.
 
We wondered whether re-
duced availability during the first weeks of life is particular
to the BDC2.5 antigen or can be generalized to other islet
cell antigens. Relevant data on a few other islet antigen/
TCR pairs have been reported—in all cases pertaining to a
viral protein artificially expressed on beta cells. In mice dis-
playing influenza hemagglutinin on beta cells, activated hem-
agglutinin-specific T cells were found throughout the
peripheral lymphoid organs, and insulitis or diabetes could
occur before 3 wk of age (37–39). In animals synthesizing
SV40 T antigen in beta cells, activated T cells were con-
fined to the PLNs, MLNs, and Peyer’s patches, and could
be detected already 1 wk after birth (40). These findings ar-
gue that unavailability of islet antigens in juvenile animals
may not be a general phenomenon. However, both systems
have complications: T cells recognizing hemagglutinin can
cross-react with murine self-antigens (41); SV40 T antigen
is an oncogene whose expression provokes hyperplasia, tu-
mors, and probably cell damage (42). We sought to reex-
amine this issue with an antigen/TCR pair not known to
be subject to such complications.
RIP-mOVA tg mice express a membrane-bound form
of OVA under the dictates of the insulin promoter, al-
though significant amounts of OVA are made by both
pancreatic islet beta cells and kidney proximal tubule cells;
OT-I transgenics express the TCR genes from an MHC
class I–restricted, OVA-specific T cell clone (20). When
naive OT-I T cells were transferred into RIP-mOVA
mice on the C57Bl/6 genetic background, proliferating
CD8
 
1
 
 cells appeared specifically in the LNs draining the
pancreas and kidney, the result of “cross-presentation” of
the OVA epitope by bone marrow–derived (presumably
dendritic) cells (20, 43). Thus, T cell activation in this
system appeared to be nearly as specific as in the BDC2.5
system.
Figure 4. Proliferation of transferred BDC2.5 cells in the PLNs occurs
before islet cell infiltration. In a representative experiment, a cohort of
Ca0/NOD mice were injected with 5 3 107 CFSE-labeled BDC2.5
spleen cells and subsequently analyzed for CFSE dilution in PLNs and
ILNs at various times after transfer. The “proliferation index” shown for
each histogram is obtained by dividing the fraction of proliferating cells
by the fraction of nonproliferating cells (gates as shown). Insulitis values
on right: number of infiltrated islets over the total number of islets scored.
Figure 5. A comparison be-
tween adult and 10-d-old
BDC2.5 mice as donors and re-
cipients in the transfer model. (A)
5 3 107 T cells from 10-d-old or
adult BDC2.5 donors were
transferred to adult Ca0/NOD
recipients. The graph is a sum-
mary of several independent ex-
periments, showing the prolifer-
ation index of CD41Vb41 T
cells in PLNs at different time
points, calculated as for Fig. 4;
each dot represents an individual
mouse. (B) BDC2.5 donor T
cells were transferred to adult or
10-d-old Ca0/NOD mice, as in-
dicated (proliferation index as
above).336 How Do T Cells Encounter Autoantigens?
As expected, and as illustrated in Fig. 6, proliferating
OT-I T cells were found in both the PLNs and renal LNs
(RLNs) on day 3 after transfer into adult hosts. In contrast,
no proliferating cells were detected in the PLNs after intro-
duction into 10-d-old recipients, although they were ob-
served in significant numbers in the RLNs of these animals.
Thus, the inability of APCs in the PLNs of very young
mice to trigger islet-reactive T cells is not antigen specific,
does not depend on the class of MHC restricting element,
and is not a peculiarity of the NOD genetic background.
Interestingly, the defect is not a general property of LN
APCs in juvenile animals, as those associated with the
RLNs are quite competent.
Discussion
This study focused on the events that trigger autoim-
mune attack of the pancreas—in particular where and
when islet-reactive T cells first encounter antigen. Tackling
these questions was facilitated by the use of BDC2.5 TCR
tg mice, as the early events of diabetes pathogenesis are par-
ticularly clear and synchronous in these animals.
The Site of Initial Encounter. The first indication that
BDC2.5 T cells are initially stimulated in the vicinity of the
pancreas came from monitoring the activation state of T
cells at various sites in the periphery of prediabetic
BDC2.5/NOD tg mice. Activated cells (expressing high
levels of CD69 and CD44, and low levels of CD62L) were
found within the islets and PLNs, but not in the spleen or
in the many other LNs examined, including the MLNs
which drain the pancreas more distally (Fig. 1, A and B).
Results from the transfer system provided support for the
notion that BDC2.5 T cells are initially stimulated in the
pancreas surroundings (Fig. 3 B), and further established
that they encounter antigen first in the PLNs rather than
within the islets (Fig. 4). These findings argue strongly
against a role for molecular mimicry in the BDC2.5 sys-
tem—had the initial stimulus been viral or dietary, we
should have seen activated/proliferating T cells at other lo-
cations, not strictly confined to the vicinity of the pancreas.
How does the BDC2.5 antigen arrive in the PLNs? A
definitive answer to this question will probably not come
until this antigen has been identified. At present, we know
only that it is associated with the membrane fraction of beta
cell vesicular structures (44), and that its presentation may
depend on intact vesicles (our unpublished results). A likely
possibility is that the antigen is picked up in the islets by
immature DCs through phagocytosis or micropinocytosis,
and is ferried to the PLNs via afferent lymphatic vessels, co-
incident with DC maturation. Certainly, DCs are present
in early insulitic lesions, even before the arrival of lympho-
cytes (45–47). It is also possible that beta cell proteins are,
themselves, transported to the PLNs through the afferent
lymphatics, and it is there that the BDC2.5 antigen is taken
up, processed, and presented. Incorporation of antigens
into vesicles seems not to be necessary for effective trans-
port to the PLNs because very diverse beta cell neoantigens
appear to be presented in this node, such as membrane-
bound OVA (20) and nuclear SV40 T antigen (40).
That beta cell antigens would be picked up by DCs in
the islets, be ferried to the draining PLNs, be presented
there to circulating naive T cells, and finally provoke those
with anti-beta cell reactivity to invade the islets would be a
sequence of events nicely analogous to the prevailing para-
digm on antigen surveillance (13). As discussed below, this
scenario is also consistent with the little existing data on
standard NOD mice. It remains to fill in the many missing
details.
The Time of Initial Encounter—Checkpoint 1. The trans-
fer system permitted us to address another critical issue
concerning the events triggering autoimmune diabetes. In-
sulitis is not detectable in standard NOD mice before 4–6
wk of age, a delay classically considered to reflect the time
it takes to activate islet-reactive T cells and expand them to
high numbers. However, BDC2.5 TCR tg mice, with
their enormous preformed antiislet repertoire, were found
to exhibit a similar lag before the initiation of insulitis (14),
prompting the speculation that diabetes progression is regu-
lated, the transition to insulitis constituting a first check-
point (14, 36). In theory, checkpoint 1 could reflect a defi-
ciency in either T cell competence or antigen availability.
To distinguish between the two, we performed crisscross
transfer experiments, introducing 10-d-old or adult donor
cells into adult hosts, as well as adult donors into 10-d-old
or adult hosts. The defect appears to be in how antigen is
made available, as both types of T cells proliferated in the
PLNs after transfer into adult hosts (Fig. 5 A), whereas
adult donors proliferated only in adult but not in 10-d-old
hosts (Fig. 5 B, and data not shown).
Reduced availability of the BDC2.5 antigen in the PLNs
of very young mice could have several roots. One class of
explanations invokes the antigen itself—it may not be syn-
thesized yet, may be made at too low a level, or may not be
in the appropriate state. The first possibility is ruled out by
the finding that preactivated, rather than naive, BDC2.5 T
cells can infiltrate the islets within days after transfer into
Figure 6. Proliferation of OVA-specific CD81 T cells in adult and 10-
d-old RIP-mOVA mice. Recipients were injected with 2 3 107 spleno-
cytes from OT-I transgenic mice, and loss of CFSE by proliferation was
evaluated in gated CD81 T cells in ILNs, RLNs, and PLNs (see above)
67 h after transfer.337 Höglund et al.
neonatal NOD recipients (48). However, this result does
not exclude the other two possibilities because activated T
cells can be stimulated by lower concentrations of antigen
than can naive cells (25), and because effective release to
the draining LNs could depend on antigen being in a par-
ticular form or subcellular compartment, e.g., part of a
multiprotein complex or encased within a vesicle. Evaluat-
ing these possibilities will require a comparison of the ef-
fective concentration of BDC2.5 antigen in the LNs of dif-
ferent-aged animals, possible through in vitro presentation
assays, but difficult and arduous given the scarcity of islets
in very young mice (our unpublished observations).
A second class of explanations for early BDC2.5 antigen
unavailability invokes the APCs—it may be that the rele-
vant antigen is perfectly available, but that the appropriate
APCs for ferrying it to or presenting it in the PLNs are at
fault. This immaturity may affect homing of DCs to the
pancreas, their ability to acquire antigens once there, or in
their traffic onwards to the PLNs. There is precedent for
defective APC function in neonates in other contexts (49,
50). Yet, our results suggest that the APC defect should be
a regional one, given that the RLNs of 10-d-old mOVA
hosts were quite capable of supporting proliferation of trans-
ferred naive OT-I cells (Fig. 6), and the pancreas may thus
be somehow special. Perhaps different populations of DC
precursors reside in the pancreas and kidney of very young
animals, or perhaps there are different cytokine milieus in
the two organs, that in the pancreas being suboptimum for
DC mobilization (due, for example, to reduced levels of
TNF-a, GM-CSF, or IL-4 [13, 51]). The appearance of
DCs in the pancreas may require particular metabolic or en-
docrine changes occurring at that time (45). Refining the
transfer system by incorporating mutant or Ab-treated do-
nors or hosts should aid us in distinguishing between these
various possibilities.
Whatever the explanation, the events underlying this
transition are not specific to NOD mice, as checkpoint 1 is
also observed when the BDC2.5 transgene is crossed onto
the C57Bl/6 genetic background (17).
Generality. It is important to consider whether our
conclusions about BDC2.5 T cells and the antigen they
recognize are generalizable. The original BDC2.5 clone
was isolated rather late in disease progression, from pooled
spleen and LNs of a diabetic NOD female (15), so one
might question its relevance to disease initiation. However,
it has already been demonstrated that BDC2.5 T cells can
engender full-blown diabetes in the absence of other lym-
phocytes (14), and we show here that no other lympho-
cytes are required for BDC2.5 cells to access their antigen
in the PLNs (Fig. 3 C). It may also be worth noting that
the BDC2.5 antigen has properties similar to the antigens
recognized by several other mouse (44) and human (52) is-
let-reactive T cell clones. Nonetheless, it would be useful
to compare the behavior of other diabetes-provoking anti-
gens and the corresponding diabetogenic T cells at the time
of disease initiation.
The little existing data on standard NOD mice are gen-
erally consistent with the observations on BDC2.5 TCR
transgenics. Three findings are in line with the notion that
initial stimulation of islet-reactive T cells occurs in the
PLNs: (a) alloxan-mediated destruction of the pancreas of
perinatal NOD animals prevented the emergence of poten-
tially diabetogenic T cells, arguing against primary activa-
tion at extrapancreatic sites (53); (b) treating juvenile NOD
animals with anti-CD40 ligand or anti-b7 integrin blocked
insulitis, but did not prevent the appearance of islet-reac-
tive T cells, indicating that priming need not occur within
the islets (54, 55); and (c) DCs in the PLNs of NOD ani-
mals indeed seem to present islet-derived antigens (56). No
existing results favor or disfavor the idea that presentation
of beta cell antigens is compromised in the PLNs of stan-
dard NOD mice at a very young age, although there is
clear evidence of a checkpoint 1 at z3 wk (36).
In conclusion, autoimmune diabetes in BDC2.5 TCR tg
mice is initiated by developmentally regulated presentation
of islet beta cell antigens in the PLNs, and this is most likely
true for standard NOD mice. It will be interesting to see
whether this phenomenon occurs in other autoimmune
diseases as well.
We thank the Diabetes Group for discussion, C. Carnaud for mice, C. Ebel for help with cytofluorimetric
analyses, T. Ding for sections, J. Hergueux and P. Nathan for assistance, and P. Michel, F. Fischer, and V.
Louerat for maintaining the mice. 
This work was supported by institute funds from the Institut National de la Santé et de la Recherche Médi-
cale, the Centre National de la Recherche Scientifique, the Hôpital Universitaire de Strasbourg, and Bristol-
Myers Squibb, by grants from the Juvenile Diabetes Foundation International (to D. Mathis and C.
Benoist), the EC-Biotech program (PL962151; to D. Mathis and C. Benoist), the National Health and
Medical Research Council of Australia (to W. Heath), and the Cooperative Research Center for Vaccine
Technology (to W. Heath). P. Höglund was supported by the Wenner-Gren Foundations.
Address correspondence to Christophe Benoist and Diane Mathis, IGBMC, BP 163, 67404 Illkirch Cedex,
France. Phone: 33-3-88-65-32-00; Fax: 33-3-88-65-32-46; E-mail: cb and dm@igbmc.u-strasbg.fr
Received for publication 11 September 1998 and in revised form 9 November 1998.338 How Do T Cells Encounter Autoantigens?
References
1. Bach, J.F. 1994. Insulin-dependent diabetes mellitus as an au-
toimmune disease. Endocr. Rev. 15:516–542.
2. Tisch, R., and H. McDevitt. 1996. Insulin-dependent diabe-
tes mellitus. Cell. 85:291–297.
3. Bach, J.F., and D. Mathis. 1997. 70th forum in immunology:
the NOD mouse. Res. Immunol. 148:285–286.
4. Leslie, R.D., and R.B. Elliott. 1994. Early environmental
events as a cause of IDDM. Evidence and implications. Dia-
betes. 43:843–850.
5. Herrath, M.G., A. Holz, D. Homann, and M.B.A. Oldstone.
1998. Role of viruses in type I diabetes. Semin. Immunol. 10:
87–100.
6. Singh, B., S. Prange, and A.M. Jevnikar. 1998. Protective
and destructive effects of microbial infection in insulin-depen-
dent diabetes mellitus. Semin. Immunol. 10:79–86.
7. Wong, F.S., and C.A. Janeway, Jr. 1997. The role of CD4
and CD8 T cells in type I diabetes in the NOD mouse. Res.
Immunol. 148:327–332.
8. Kay, T.W., H.L. Chaplin, J.L. Parker, L.A. Stephens, and
H.E. Thomas. 1997. CD41 and CD81 T lymphocytes: clari-
fication of their pathogenic roles in diabetes in the NOD
mouse. Res. Immunol. 148:320–327.
9. Nepom, G.T. 1995. Glutamic acid decarboxylase and other
autoantigens in IDDM. Curr. Opin. Immunol. 7:825–830.
10. Roep, B.O. 1996. T-cell responses to autoantigens in
IDDM. The search for the Holy Grail. Diabetes. 45:1147–
1156.
11. Wegmann, D.R. 1996. The immune response to islets in ex-
perimental diabetes and insulin-dependent diabetes mellitus.
Curr. Opin. Immunol. 8:860–864.
12. Butcher, E.C., and L.J. Picker. 1996. Lymphocyte homing
and homeostasis. Science. 272:60–66.
13. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells
and the control of immunity. Nature. 392:245–252.
14. Katz, J.D., B. Wang, K. Haskins, C. Benoist, and D. Mathis.
1993. Following a diabetogenic T cell from genesis through
pathogenesis. Cell. 74:1089–1100.
15. Haskins, K., M. Portas, B. Bradley, D. Wegmann, and K.J.
Lafferty. 1988. T-lymphocyte clone specific for pancreatic is-
let antigen. Diabetes. 37:1444–1448.
16. Haskins, K., and M. McDuffie. 1990. Acceleration of diabe-
tes in young NOD mice with a CD41 islet-specific T-cell
clone. Science. 249:1433–1436.
17. Gonzalez, A., J.D. Katz, M.G. Mattei, H. Kikutani, C.
Benoist, and D. Mathis. 1997. Genetic control of diabetes
progression. Immunity. 7:873–883.
18. Philpott, K.L., J.L. Viney, G. Kay, S. Rastan, E.M. Gardiner,
S. Chae, A.C. Hayday, and M.J. Owen. 1992. Lymphoid de-
velopment in mice congenitally lacking T cell receptor ab-
expressing cells. Science. 256:1448–1452.
19. Mombaerts, P., J. Iacomini, R.S. Johnson, K. Herrup, S.
Tonegawa, and V.E. Papaioannou. 1992. RAG-1-deficient
mice have no mature B and T lymphocytes. Cell. 68:869–877.
20. Kurts, C., W.R. Heath, F.R. Carbone, J. Allison, J.F. Miller,
and H. Kosaka. 1996. Constitutive class I–restricted exoge-
nous presentation of self antigens in vivo. J. Exp. Med. 184:
923–930.
21. Cosgrove, D., D. Gray, A. Dierich, J. Kaufman, M. Lemeur,
C. Benoist, and D. Mathis. 1991. Mice lacking MHC class II
molecules. Cell. 66:1051–1066.
22. Trowbridge, I.S., J. Lesley, R. Schuite, R. Human, and J.
Trotter. 1982. Biochemical characterization and cellular dis-
tribution of a polymorphic, murine cell-surface glycoprotein
expressed on lymph node cells. Immunogen. 15:299–305.
23. Gallatin, W.M., I.L. Weissman, and E.C. Butcher. 1983. A
cell-surface molecule involved in organ-specific homing of
lymphocytes. Nature. 304:30–34.
24. Pircher, H., N. Rebai, M. Groettrup, C. Grégoire, D.E.
Speiser, M.P. Happ, E. Palmer, R.M. Zinkernagel, H. Hen-
gartner, and B. Malissen. 1992. Preferential positive selection
of Va21CD81 T cells in mouse strains expressing both H-2k
and T cell receptor Vaa haplotypes: determination with a
Va2-specific monoclonal antibody. Eur. J. Immunol. 22:
399–404.
25. Kurts, C., J.F.A.P. Miller, R.M. Subramanian, F.R. Car-
bone, and W.R. Heath. 1998. MHC class I–restricted cross-
presentation is biased towards high dose antigens and those
released during cellular destruction. J. Exp. Med. 188:409–414.
26. Bruce, J., F.W. Symington, T.J. McKearn, and J. Sprent.
1981. A monoclonal antibody discriminating between subsets
of T and B cells. J. Immunol. 127:2496–2501.
27. Ceredig, R., J.W. Lowenthal, M. Nabholz, and H.R. Mac-
Donald. 1985. Expression of interleukin-2 receptors as a dif-
ferentiation marker on intrathymic stem cells. Nature. 314:
98–100.
28. Katz, J., C. Benoist, and D. Mathis. 1993. Major histocom-
patibility complex class I molecules are required for the de-
velopment of insulitis in non-obese diabetic mice. Eur. J. Im-
munol. 23:3358–3360.
29. Wicker, L.S., E.H. Leiter, J.A. Todd, R.J. Renjilian, E.
Peterson, P.A. Fischer, P.L. Podolin, M. Zijlstra, R. Jaenisch,
and L.B. Peterson. 1994. b2-microglobulin-deficient NOD
mice do not develop insulitis or diabetes. Diabetes. 43:500–504.
30. Serreze, D.V., E.H. Leiter, G.J. Christianson, D. Greiner,
and D.C. Roopenian. 1994. Major histocompatibility com-
plex class I-deficient NOD-B2mnull mice are diabetes and in-
sulitis resistant. Diabetes. 43:505–509.
31. Sumida, T., M. Furukawa, A. Sakamoto, T. Namekawa, T.
Maeda, M. Zijlstra, I. Iwamoto, T. Koike, S. Yoshida, H.
Tomioka, and M. Taniguchi. 1994. Prevention of insulitis
and diabetes in b2-microglobulin-deficient non-obese dia-
betic mice. Int. Immunol. 6:1445–1449.
32. Wang, B., A. Gonzalez, C. Benoist, and D. Mathis. 1996.
The role of CD81 T cells in initiation of insulin-dependent
diabetes mellitus. Eur. J. Immunol. 26:1762–1769.
33. Wong, F.S., I. Visintin, L. Wen, R.A. Flavell, and C.A. Jane-
way, Jr. 1996. CD8 T cell clones from young nonobese dia-
betic (NOD) islets can transfer rapid onset of diabetes in
NOD mice in the absence of CD4 cells. J. Exp. Med. 183:
67–76.
34. Serreze, D.V., H.D. Chapman, D.S. Varnum, I. Gerling,
E.H. Leiter, and L.D. Shultz. 1997. Initiation of autoimmune
diabetes in NOD/Lt mice is MHC class I-dependent. J. Im-
munol. 158:3978–3986.
35. Lühder, F., P. Höglund, J.P. Allison, C. Benoist, and D.
Mathis. 1998. Cytotoxic T lymphocyte–associated antigen 4
regulates the unfolding of autoimmune diabetes. J. Exp. Med.
187:427–432.
36. André, I., A. Gonzalez, B. Wang, J. Katz, C. Benoist, and D.
Mathis. 1996. Checkpoints in the progression of autoim-
mune disease: lessons from diabetes models. Proc. Natl. Acad.
Sci. USA. 93:2260–2263.
37. Scott, B., R. Liblau, S. Degermann, L.A. Marconi, L. Ogata,
A.J. Caton, H.O. McDevitt, and D. Lo. 1994. A role for339 Höglund et al.
non-MHC genetic polymorphism in susceptibility to sponta-
neous autoimmunity. Immunity. 1:73–82.
38. Sarukhan, A., A. Lanoue, A. Franzke, N. Brousse, J. Buer,
and H. von Boehmer. 1998. Changes in function of antigen-
specific lymphocytes correlating with progression towards di-
abetes in a transgenic model. EMBO (Eur. Mol. Biol. Organ.)
J. 17:71–80.
39. Morgan, D.J., R. Liblau, B. Scott, S. Fleck, H.O. McDevitt,
N. Sarvetnick, D. Lo, and L.A. Sherman. 1996. CD81 T
cell-mediated spontaneous diabetes in neonatal mice. J. Im-
munol. 157:978–983.
40. Forster, I., and I. Lieberam. 1996. Peripheral tolerance of
CD4 T cells following local activation in adolescent mice.
Eur. J. Immunol. 26:3194–3202.
41. Bruno, L., H. von Boehmer, and J. Kirberg. 1996. Cell divi-
sion in the compartment of naive and memory T lympho-
cytes. Eur. J. Immunol. 26:3179–3184.
42. Adams, T.E., S. Alpert, and D. Hanahan. 1987. Non-toler-
ance and autoantibodies to a transgenic self antigen expressed
in pancreatic beta cells. Nature. 325:223–228.
43. Heath, W.R., C. Kurts, J.F.A.P. Miller, and F.R. Carbone.
1998. Cross-tolerance: a pathway for inducing tolerance to
peripheral tissue antigens. J. Exp. Med. 187:1549–1553.
44. Bergman, B., and K. Haskins. 1994. Islet-specific T-cell
clones from the NOD mouse respond to beta-granule anti-
gen. Diabetes. 43:197–203.
45. Dahlen, E., K. Dawe, L. Ohlsson, and G. Hedlund. 1998.
Dendritic cells and macrophages are the first and major pro-
ducers of TNF-alpha in pancreatic islets in the nonobese dia-
betic mouse. J. Immunol. 160:3585–3593.
46. Lo, D., C.R. Reilly, B. Scott, R. Liblau, H.O. McDevitt,
and L.C. Burkly. 1993. Antigen-presenting cells in adop-
tively transferred and spontaneous autoimmune diabetes. Eur.
J. Immunol. 23:1693–1698.
47. Jansen, A., F. Homo-Delarche, H. Hooijkaas, P.J. Leenen,
M. Dardenne, and H.A. Drexhage. 1994. Immunohis-
tochemical characterization of monocytes-macrophages and
dendritic cells involved in the initiation of the insulitis and
beta-cell destruction in NOD mice. Diabetes. 43:667–675.
48. Katz, J.D., C. Benoist, and D. Mathis. 1995. T helper cell
subsets in insulin-dependent diabetes. Science. 268:1185–
1188.
49. Lu, C.Y., E.G. Calamai, and E.R. Unanue. 1979. A defect in
the antigen-presenting function of macrophages from neona-
tal mice. Nature. 282:327–329.
50. Rafii-Tabar, E., and A.A. Czitrom. 1986. Ontogeny of prim-
ing of cytotoxic T cells to minor alloantigens: the develop-
ment of direct priming precedes that of cross-priming. Eur. J.
Immunol. 16:1025–1027.
51. Yang, X.-D., R. Tisch, S.M. Singer, Z.A. Cao, R.S. Liblau,
R.D. Schreiber, and H.O. McDevitt. 1994. Effect of tumor
necrosis factor a on insulin-dependent diabetes mellitus in
NOD mice. I. The early development of autoimmunity and
the diabetogenic process. J. Exp. Med. 180:995–1004.
52. Roep, B.O., S.D. Arden, R.R. de Vries, and J.C. Hutton.
1990. T-cell clones from a type-1 diabetes patient respond to
insulin secretory granule proteins. Nature. 345:632–634.
53. Larger, E., C. Becourt, J.F. Bach, and C. Boitard. 1995. Pan-
creatic islet beta cells drive T cell–immune responses in the
nonobese diabetic mouse model. J. Exp. Med. 181:1635–
1642.
54. Balasa, B., T. Krahl, G. Patstone, J. Lee, R. Tisch, H.O.
McDevitt, and N. Sarvetnick. 1997. CD40 ligand-CD40 in-
teractions are necessary for the initiation of insulitis and dia-
betes in nonobese diabetic mice. J. Immunol. 159:4620–4627.
55. Yang, X.D., H.K. Sytwu, H.O. McDevitt, and S.A. Michie.
1997. Involvement of beta 7 integrin and mucosal addressin
cell adhesion molecule-1 (MAdCAM-1) in the development
of diabetes in obese diabetic mice. Diabetes. 46:1542–1547.
56. Clare-Salzler, M., and Y. Mullen. 1992. Marked dendritic
cell-T cell cluster formation in the pancreatic lymph node of
the non-obese diabetic mouse. Immunology. 76:478–484.